Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Expert Opin Ther Targets. 2021 Oct;25(10):847-864. doi: 10.1080/14728222.2021.2005026. Epub 2021 Dec 7.
The pathogenesis of retinal vein occlusion (RVO) is extremely complex and includes several mediators. These mediators represent potential drug targets that can be used in the development of intravitreal drugs.
PubMed/MEDLINE databases were accessed between April-May 2021 to find the most relevant scientific papers regarding drug targets and therapeutic implications in RVO, focusing on current therapeutic options and potential cornerstones of future advances in treatment.
Before the introduction of intravitreal therapies, the visual outcome following a diagnosis of RVO was extremely poor. Anti-VEGF and corticosteroid treatments have radically changed RVO prognosis, helping to preserve patients' visual function and their quality of life. According to current clinical data, anti-VEGF and corticosteroid drugs are associated with both pros and cons; the present recommendation is to employ anti-VEGF molecules as a first-line treatment. Advances in our understanding of the biomolecular characteristics of RVO offer a solid basis for the development of new therapeutic targets and treatments.
视网膜静脉阻塞（RVO）的发病机制极其复杂，涉及多种介质。这些介质代表了潜在的药物靶点，可用于开发眼内药物。
2021 年 4 月至 5 月期间，我们检索了 PubMed/MEDLINE 数据库，以找到有关 RVO 药物靶点和治疗意义的最相关科学论文，重点关注当前的治疗选择和未来治疗进展的潜在基石。
在引入眼内治疗之前，RVO 诊断后的视力预后极差。抗 VEGF 和皮质类固醇治疗极大地改变了 RVO 的预后，有助于保护患者的视力和生活质量。根据目前的临床数据，抗 VEGF 和皮质类固醇药物都有其优缺点；目前的建议是将抗 VEGF 分子作为一线治疗药物。我们对 RVO 生物分子特征的理解的进步为新的治疗靶点和治疗方法的发展提供了坚实的基础。
